Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2007-12-18
2007-12-18
Yaen, Christopher H. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
active
10003211
ABSTRACT:
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
REFERENCES:
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: WO-92/00329 (1992-01-01), None
patent: WO94/046679 (1994-03-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO97/03678 (1997-02-01), None
patent: WO-97/03687 (1997-02-01), None
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.
Lazar et al. Molecular and Cellular Biology 8:1247-1252, 1988.
Bowie et al. Science, 247:1306-1310, 1990.
Gommerman et al (Nature Rev. Immunol. 2003; 3:642-655).
Trethewey P Dimens Crit Care Nurs 2004;23(3):111-115.
http://reutershealth.com/wellcomnnected/doc63.html, Aug. 3, 2004.
Mendlovic et al Proc. Natl. Acad. Sci. USA Apr. 1968;85:2260-2264.
Smolen JS Arthritis Research May 2002; 4(Suppl. 3):S25-S30.
Alimzhanov et al., 1997, Proc. Natl. Acad. Sci., 94:9302-9307, “Abnormal development of secondary lymphoid tissues in lymphotoxin Beta-deficient mice”.
Androlewicz et al., 1992, J. of Biol. Chem., 267:2542-2547, “Lymphotoxin Is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma”.
Arulanandam et al., 1993, J. Exp. Med., 177:1439-1450, “A Soluble Multimeric Recombinant CD2 Protein Identified CD48 As A Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands During The Evolution of Humans and Mice”.
Banks et al., 1995, J. of Immunol. 155:1687-1693, “Lymphotoxin-Alpha-Deficient Mice”.
Barnetson et al., 1993, Mosby-Year Book Europe Ltd., 22.1-22.12, “Hypersensitivity-Type I V”.
Briskin et al., 1993, Nature, 363:461-464, “MAdCAM-1 Has Homology TO Immunoglobulin And Mucin-Like Adhesion Receptors And TO IgA1”.
Browning J., Androlewicz, M. et al., 1991, J. of Immunol. 147:1230-1237, “Lymphotoxin And An Associated 33-kDa Glycoprotein Are Expredded On the Surface Of An Activated Human T Cell Hybridoma”.
Browning J., Douglas, I., et al., 1995, American Association of Immunol., 33-46, “Characterization of Surface Lymphotoxin Forms”.
Browning, J., Ngam-ek, A., et al., 1993, 73:847-856, “Lymphotoxin-Beta, A Novel Member of the TNF Family That Forms a Heteromeric Complex With Lymphotoxin On the Cell Surface”.
Cavert, W. et al., 1997, 276:960-964, “Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection”.
Chen, C. et al., 1995, Trends in Biol. Sci., 20:465-470, “AU-rich Elements: Characterization and Importance In mRNA Degradation”.
Crowe, P. et al., 1994, Science, 264:707-710, “A Lymphotoxin-Beta-Specific Receptor”.
DeTongi, P. et al., 1994, Science, 264:703-706, “Abnormal Development Of PEripheral Lymphoid Organs in Mice Deficient in Lymphtoxin”.
Dijkstra et al., 1985, Immunology, 55:23-30, “Marginal Zone Macrophages Identified BY A Monoclonal Anitbody: Characterization of Immuno-and Enzyme-Histochemical Properties and Functional Capacities”.
Gonzalez et al., 1998, J. Exp. Med., 187:997-1007, “The Sequential Role of Lymphotoxin and B Cells in the Development of Splenic Follicles”.
Han et al., 1995, American Association iof Immunol., 556-567, “Cellular Interaction in Germinal Centers”.
Heath et al., 1995, Nature, 377:740-744, “Follicular Dendritic Cells And Human Immunodeficiency Virus Infectivity”.
Hwang et al., 1980, Proc. Natl. Acad., 77:4030-4034, “Hepatic Uptake And Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study”.
Kraal, Geroge, 1992, Academic Press, 132:31-74, “Cells In the Marginal Zone of the Spleen”.
Kraal and Janse, 1986, Immunology, 58:665-669, “Marginal Metallophic Cells Of the Mouse Spleen Identified By a Monoclonal Antibody”.
Kraal, Rodrigues, et al., 1989, Immunology, 68:227-232, “Lymphocyte Migration in the Spleen: the Effect of Macrophage Elimination”.
Kraal, Schornagel, et al., 1995, American Journal of Pathology, 147:763-771, “Expression of the Mucosal Vascular Addressin, MAdCAM-1, on Sinus-Lining Cells in the Spleen”.
Kratz et sl., 1996, J. Exp. Med., 183:1461-1472, “Chronic Imflammation Caused by Lymphotoxin Is Lymphoid Neogenesis”.
Laman et al., 1996, Critical Reviews in Immunol., 16:59-108, “Functions of CD40 and Its Ligang, gp39 (CD40L)”.
Lane et al., 1992, Eur. J. Immunol., 22:2573-2578, “Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell -dependent activation of B lymphocytes”.
Langer, 1982, Chemtech, February, 98-105, “Controlled release of macromolecules”.
Langer, Brem, et al., 1981, J. of Biomed. Materials, 15:267-277, “Biocompatibility of polymeric delivery systems for macromolecules”.
Le Hir, et al., 1996, J. Exp. Med., 183:2367-2372, “Differentation of Follicular Dendric Cells and Full Antibody Responses Reuqire Tumor Necrosis Factor Receptor-1 Signaling”.
Mackay et al., 1997, Eur. J. Immunol., 27:2033-2042, “Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice”.
MacLennan et al., 1993, Blackwell Scientific Publications, 5:13-30, “The Structure and Function of Secondary Lymphoid Tissue”.
Maeda et al., 1992, J. of Immunol., 148:2340-2347, “Murine Follicular Dendritic Cells and Low Affinity Fc Receptors For IgE (FceRII)1”.
Male et al., 1993, Mosby-Year Book Europe, 3rd ed., 1:1.1-1.12, “Introduction to the Immune System”.
Matsumoto, Chaplin, et al., 1997, Immunol. Reviews, 156:137-144, :Lymphotoxin-alpha-deficient and TNF receptor-1-deficient mice define developmental and functional characteristics of germinal centers.
Matsumoto, Huang, et al., 1997, J. Exp. Med., 186:1997-2004, “Distinct Roles of Lymphotoxin alpha and the Type 1 Tumor Necrosis Factor (TNF) Receptor in the Establishment of Follicular Dendritic Cells form Non-Bone Marrow-derived Cells”.
Matsumoto, Lo, et al., 1996, Nature, 382:462-466, “Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice”.
Matsumoto, Mariathasan, et al., 1996, Science, 271:1289-1291, “Role of Lymphotoxin and the Type 1 THNF Receptor in the Formation of Germinal Centers”.
Miller et al., 1993, J. Exp. Med., 178:211-222, “Specific Interaction of Lymphocyte Function-associated Antigen 3 with CD2 Can Inhibit T Cell Responses”.
Mohan et al., 1995, J. of Immunol., 154:1470-1480, “Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis1”.
Morrison et al., 1992, Annu. Rev. Immunol., 10:239-265, “In Vitro Antibodies: Strategies for Production and Application”.
Morrison, Johnson, et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855, “Chemeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”.
Nakache et al., 1989, Nature, 337:179-181, “The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes”.
Neumann et al., 1996, J. Exp. Med., 184:259-264, “Defective Peyer's Patch Organogenesis in Mice Lacking the 55-kD Receptor for Tumor Necrosis Factor”.
Pfeffer et al., 1993, Cell, 73:457-467, “Mice Deficient for the 55 kd Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, yet Succumb to L. monocytogenes Infection”.
Picarella et al., 1992, Proc. Natll. Acad. Sci., 89:10036-1004
Browning Jeffrey L.
Hochman Paula S.
MacKay Fabienne
Rennert Paul D.
Biogen Idec MA Inc.
Howley Cristin E.
Lahive and Cockfield, LLP.
Mandragouras Esq. Amy E.
Yaen Christopher H.
LandOfFree
Soluble lymphotoxin-β receptors as therapeutic agents... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble lymphotoxin-β receptors as therapeutic agents..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble lymphotoxin-β receptors as therapeutic agents... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3881999